{"id":"amlodipine-placebos","safety":{"commonSideEffects":[{"rate":"8-10","effect":"Peripheral edema"},{"rate":"7-8","effect":"Headache"},{"rate":"4-6","effect":"Flushing"},{"rate":"4-5","effect":"Fatigue"},{"rate":"3-4","effect":"Dizziness"},{"rate":"2-3","effect":"Palpitations"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Amlodipine placebos","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:59:22.890826+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:59:36.935682+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:59:28.393562+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Amlodipine placebos","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:59:28.699546+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Voltage-gated L-type calcium channel blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:59:29.749294+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200402/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:59:29.417318+00:00"}},"_dailymed":null,"aiSummary":"Amlodipine placebos, marketed by Shenzhen Ausa Pharmed Co., Ltd., currently hold a position in the pharmaceutical market with a key composition patent expiring in 2028. The primary strength of the product lies in its established market presence, leveraging the well-known efficacy and safety profile of amlodipine. The primary risk is the potential increase in competition post-patent expiry in 2028, which could impact revenue and market share.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine selectively blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, preventing calcium influx and causing vasodilation. This reduces peripheral vascular resistance and decreases blood pressure. It also reduces myocardial oxygen demand by decreasing heart rate and contractility.","oneSentence":"Amlodipine is a calcium channel blocker that relaxes blood vessels and reduces heart workload to lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:18.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:59:36.935816+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris (chronic stable angina and vasospastic angina)"}]},"trialDetails":[{"nctId":"NCT05312892","phase":"PHASE1, PHASE2","title":"Sympathetic Mechanisms in Obesity-Crossover Design","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-05-20","conditions":"Obesity, Hypertension","enrollment":12},{"nctId":"NCT06236061","phase":"PHASE3","title":"Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-08","conditions":"Hypertension","enrollment":718},{"nctId":"NCT05103332","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2021-11-05","conditions":"Hypertension","enrollment":663},{"nctId":"NCT02699645","phase":"PHASE3","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial","status":"COMPLETED","sponsor":"The George Institute","startDate":"2017-09-28","conditions":"Intracerebral Haemorrhage (ICH), Hypertension","enrollment":1671},{"nctId":"NCT03938389","phase":"PHASE4","title":"The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2020-02-25","conditions":"PreDiabetes, Impaired Glucose Tolerance, Obesity","enrollment":90},{"nctId":"NCT06150560","phase":"PHASE3","title":"A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-04-01","conditions":"Coarctation of Aorta, High Blood Pressure","enrollment":120},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT04518306","phase":"PHASE3","title":"Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension","status":"COMPLETED","sponsor":"George Medicines PTY Limited","startDate":"2021-06-14","conditions":"Hypertension","enrollment":755},{"nctId":"NCT04974138","phase":"PHASE4","title":"China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)","status":"RECRUITING","sponsor":"Shenzhen Ausa Pharmed Co.,Ltd","startDate":"2024-08-22","conditions":"Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L)","enrollment":32000},{"nctId":"NCT04974151","phase":"PHASE4","title":"China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype","status":"RECRUITING","sponsor":"Shenzhen Ausa Pharmed Co.,Ltd","startDate":"2024-08-22","conditions":"Hypertension, MTHFR 677 TT Genotype","enrollment":24000},{"nctId":"NCT05155137","phase":"PHASE3","title":"Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)","status":"RECRUITING","sponsor":"Hospital Moinhos de Vento","startDate":"2021-12-20","conditions":"Stroke, Cognitive Decline","enrollment":8518},{"nctId":"NCT06293261","phase":"","title":"Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2020-06-27","conditions":"Hypertension, Hypercholesterolemia","enrollment":5047},{"nctId":"NCT06780865","phase":"NA","title":"Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute of Hypertension","startDate":"2025-01-30","conditions":"Chronic Kidney Disease(CKD), Nocturnal Hypertension","enrollment":200},{"nctId":"NCT06771245","phase":"PHASE3","title":"A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-01-24","conditions":"Mild-to-moderate Essential Hypertension","enrollment":606},{"nctId":"NCT02893358","phase":"PHASE4","title":"Antihypertensive Treatment in Masked Hypertension","status":"COMPLETED","sponsor":"Yan Li","startDate":"2017-02-14","conditions":"Masked Hypertension","enrollment":320},{"nctId":"NCT06424834","phase":"PHASE2, PHASE3","title":"Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-10-10","conditions":"Angina Pectoris, Microvascular Angina, Vasospastic Angina","enrollment":150},{"nctId":"NCT02099123","phase":"PHASE4","title":"A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2015-07","conditions":"Independent Living, Disability Free Survival, Elderly","enrollment":9971},{"nctId":"NCT02620163","phase":"PHASE3","title":"Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-12","conditions":"Hypertension","enrollment":381},{"nctId":"NCT06465264","phase":"PHASE3","title":"To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2021-04-29","conditions":"Essential Hypertension","enrollment":499},{"nctId":"NCT01277822","phase":"PHASE4","title":"Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-05-30","conditions":"Hypertension","enrollment":334},{"nctId":"NCT00568178","phase":"PHASE3","title":"An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-06-01","conditions":"Proteinuria","enrollment":306},{"nctId":"NCT06275763","phase":"PHASE4","title":"Optimal Medical Treatment of Difficult-to-treat Hypertension","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2023-10-20","conditions":"Hypertension","enrollment":2500},{"nctId":"NCT06212648","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2022-03-25","conditions":"Hypertension, Essential Hypertension","enrollment":253},{"nctId":"NCT00170976","phase":"PHASE3","title":"A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-04","conditions":"HYPERTENSION","enrollment":403},{"nctId":"NCT00409760","phase":"PHASE3","title":"Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension.","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-01","conditions":"Hypertension","enrollment":1930},{"nctId":"NCT05144360","phase":"PHASE3","title":"Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and Hypertension","status":"WITHDRAWN","sponsor":"EMS","startDate":"2022-08","conditions":"Hypertension Associated, Type II Diabetes Mellitus","enrollment":""},{"nctId":"NCT05475665","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-07-14","conditions":"Essential Hypertension","enrollment":157},{"nctId":"NCT05476354","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-07-05","conditions":"Essential Hypertension","enrollment":271},{"nctId":"NCT04929600","phase":"PHASE4","title":"Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-11-28","conditions":"Hypertension, Left Ventricular Hypertrophy","enrollment":120},{"nctId":"NCT04954196","phase":"PHASE2","title":"Benefit of Amlodipine in HRT Cycle for Frozen Embryo Transfer in the Correction of Uterine Pulsatility Index","status":"WITHDRAWN","sponsor":"University Hospital, Montpellier","startDate":"2021-10-08","conditions":"Frozen Embryo Transfer","enrollment":""},{"nctId":"NCT02850081","phase":"PHASE3","title":"Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2017-06-01","conditions":"Carotid Artery Stenosis, Strokes","enrollment":31},{"nctId":"NCT03897868","phase":"PHASE2","title":"A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-03-21","conditions":"Hypertension","enrollment":248},{"nctId":"NCT03847506","phase":"PHASE4","title":"Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2018-07-05","conditions":"Hypertension, Hyperlipidemia","enrollment":127},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":106},{"nctId":"NCT03009487","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-01","conditions":"Hypertension, Hyperlipidemias","enrollment":265},{"nctId":"NCT02774460","phase":"PHASE4","title":"The Precision Hypertension Care Study","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2017-02-20","conditions":"Hypertension","enrollment":280},{"nctId":"NCT03991442","phase":"PHASE3","title":"BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2019-06-17","conditions":"Essential Hypertension","enrollment":257},{"nctId":"NCT04218552","phase":"PHASE2","title":"Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2020-02-25","conditions":"Hypertension,Essential","enrollment":176},{"nctId":"NCT03783754","phase":"NA","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study","status":"TERMINATED","sponsor":"The George Institute","startDate":"2018-08-09","conditions":"Stroke, Cerebral Small Vessel Diseases, Intracerebral Hemorrhage","enrollment":4},{"nctId":"NCT03785067","phase":"PHASE3","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study","status":"TERMINATED","sponsor":"The George Institute","startDate":"2020-02-27","conditions":"Cognitive Decline, Intracerebral Hemorrhage, Dementia, Vascular","enrollment":1},{"nctId":"NCT00412113","phase":"PHASE4","title":"A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-01","conditions":"Dyslipidemia, Hypertension","enrollment":245},{"nctId":"NCT00332761","phase":"PHASE4","title":"Caduet in an Untreated Subject Population","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-06","conditions":"Hypertension, Dyslipidemia","enrollment":220},{"nctId":"NCT01118520","phase":"PHASE2","title":"AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-09","conditions":"Abdominal Aortic Aneurysm","enrollment":224},{"nctId":"NCT02034435","phase":"PHASE4","title":"Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2013-10","conditions":"Metabolic Syndrome","enrollment":44},{"nctId":"NCT01870739","phase":"PHASE2","title":"A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10","conditions":"Hypertension","enrollment":115},{"nctId":"NCT04161001","phase":"PHASE3","title":"Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-11-20","conditions":"Hypertension, Dyslipidemia","enrollment":237},{"nctId":"NCT02979197","phase":"PHASE3","title":"Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives","status":"COMPLETED","sponsor":"Kitov Pharma Ltd","startDate":"2016-11-03","conditions":"Hypertension","enrollment":105},{"nctId":"NCT01354613","phase":"NA","title":"Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2011-04","conditions":"Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension","enrollment":14},{"nctId":"NCT01302691","phase":"PHASE3","title":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT00902538","phase":"PHASE3","title":"Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-04","conditions":"Essential Hypertension","enrollment":2204},{"nctId":"NCT00923091","phase":"PHASE3","title":"Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-06","conditions":"Essential Hypertension","enrollment":2689},{"nctId":"NCT02058823","phase":"PHASE4","title":"Intermittent Hypoxia 2: Cardiovascular and Metabolism","status":"TERMINATED","sponsor":"University Hospital, Grenoble","startDate":"2013-08-07","conditions":"Hypoxia, Sleep Apnea, Obstructive Sleep Apnea","enrollment":12},{"nctId":"NCT01838850","phase":"PHASE3","title":"Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy","status":"COMPLETED","sponsor":"Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company","startDate":"2013-04","conditions":"Essential Hypertension","enrollment":344},{"nctId":"NCT01337674","phase":"PHASE1","title":"Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-01","conditions":"Hypertension","enrollment":26},{"nctId":"NCT01101009","phase":"PHASE4","title":"Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2010-04","conditions":"Hypertension","enrollment":486},{"nctId":"NCT00185133","phase":"PHASE3","title":"Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2005-05","conditions":"Hypertension","enrollment":1900},{"nctId":"NCT03667677","phase":"PHASE4","title":"Comparison of Tandospirone, Amlodipine and Their Combination in Adults With Hypertension and Anxiety","status":"UNKNOWN","sponsor":"Chongqing Medical University","startDate":"2019-02-01","conditions":"Hypertension, Anxiety","enrollment":256},{"nctId":"NCT03231982","phase":"PHASE4","title":"Study to Confirm the Efficacy and Safety of Fixed-dose Combinations of Amlodipine and Candesartan","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2017-04-17","conditions":"Hypertension","enrollment":210},{"nctId":"NCT02172040","phase":"PHASE3","title":"Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy","status":"COMPLETED","sponsor":"Kitov Pharmaceuticals, Ltd.","startDate":"2014-06-26","conditions":"Hypertension","enrollment":152},{"nctId":"NCT01264692","phase":"PHASE2","title":"Essential Hypertension","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2011-02","conditions":"Essential Hypertension","enrollment":196},{"nctId":"NCT03088254","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2016-09-20","conditions":"Dyslipidemia With Hypertension","enrollment":126},{"nctId":"NCT03566316","phase":"PHASE3","title":"Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-11-24","conditions":"Hypertension With Hyperlipidemia","enrollment":134},{"nctId":"NCT03504735","phase":"PHASE4","title":"Caduet and TLC Intervention in Metabolic Syndrome","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2005-05-01","conditions":"Metabolic Syndrome","enrollment":53},{"nctId":"NCT01252238","phase":"NA","title":"Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2010-06","conditions":"Insulin Sensitivity, Aortic Compliance, Diastolic Function","enrollment":24},{"nctId":"NCT03210532","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2016-10-07","conditions":"Hypertension, Dyslipidemia","enrollment":129},{"nctId":"NCT03276598","phase":"PHASE4","title":"A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"1999-11-25","conditions":"Hypertension, Pharmacogenetics","enrollment":233},{"nctId":"NCT02969265","phase":"PHASE3","title":"An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2017-05-09","conditions":"Hypertension","enrollment":""},{"nctId":"NCT00446524","phase":"PHASE3","title":"Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Hypertension","enrollment":403},{"nctId":"NCT02734355","phase":"PHASE4","title":"Left Atrial Mechanical Function Improvement After Atrial Fibrillation Catheter Ablation","status":"COMPLETED","sponsor":"Research Institute for Complex Problems of Cardiovascular Diseases, Russia","startDate":"2015-11","conditions":"Atrial Fibrillation","enrollment":64},{"nctId":"NCT01237873","phase":"PHASE3","title":"Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Essential Hypertension","enrollment":150},{"nctId":"NCT02232880","phase":"PHASE2","title":"Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2014-08","conditions":"Hypertension","enrollment":1},{"nctId":"NCT01975246","phase":"PHASE3","title":"Add-on to Micamlo BP Trial","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Hypertension","enrollment":309},{"nctId":"NCT02738632","phase":"PHASE3","title":"Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-05","conditions":"Essential Hypertension","enrollment":300},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT02586311","phase":"PHASE3","title":"CKD-330 Phase 3 Trial in Amlodipine Non-responder","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2016-01","conditions":"Hypertension","enrollment":160},{"nctId":"NCT01518998","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2011-08","conditions":"Hypertension","enrollment":420},{"nctId":"NCT01692301","phase":"PHASE2","title":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Hypertension","enrollment":454},{"nctId":"NCT01911780","phase":"PHASE3","title":"Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-07","conditions":"Hypertension","enrollment":132},{"nctId":"NCT01663233","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Essential Hypertension","enrollment":266},{"nctId":"NCT01130168","phase":"PHASE1","title":"The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05","conditions":"Hypertension","enrollment":38},{"nctId":"NCT01395199","phase":"PHASE3","title":"Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2012-08","conditions":"Thalassemia, Iron Overload","enrollment":62},{"nctId":"NCT00789321","phase":"PHASE1","title":"A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":"Hypertension","enrollment":47},{"nctId":"NCT01631864","phase":"PHASE2","title":"Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Hypertension, Concurrent Obesity","enrollment":98},{"nctId":"NCT01922141","phase":"PHASE4","title":"Aliskiren Study of Safety and Efficacy in Senior Hypertensives","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05","conditions":"Hypertension","enrollment":""},{"nctId":"NCT01125254","phase":"PHASE2, PHASE3","title":"Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2008-09","conditions":"Thalassemia Major","enrollment":10},{"nctId":"NCT00437645","phase":"PHASE3","title":"Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Essential Hypertension","enrollment":1183},{"nctId":"NCT00498433","phase":"PHASE2","title":"Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-06","conditions":"Hypertension, Abdominal Obesity","enrollment":46},{"nctId":"NCT01865188","phase":"PHASE3","title":"Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Hypertension","enrollment":""},{"nctId":"NCT02177409","phase":"PHASE3","title":"Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-04","conditions":"Hypertension","enrollment":431},{"nctId":"NCT01204398","phase":"PHASE3","title":"Telmisartan+Amlodipine Fixed Dose Combination in Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-11","conditions":"Hypertension","enrollment":27},{"nctId":"NCT01255475","phase":"PHASE2, PHASE3","title":"Blood Pressure Reduction in Heart Failure","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2011-01","conditions":"Heart Failure, Cardiac Failure, Congestive Heart Failure","enrollment":21},{"nctId":"NCT00626743","phase":"PHASE1","title":"Phase I Study to Investigate the Effect on the Blood Pressure After Oral Administration of SK3530 and Amlodipine","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2008-05","conditions":"Hypertension","enrollment":13},{"nctId":"NCT01259297","phase":"PHASE3","title":"A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Cardiovascular Events","enrollment":2336},{"nctId":"NCT00281580","phase":"PHASE3","title":"Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Hypertension","enrollment":1461},{"nctId":"NCT02072330","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-03","conditions":"Grade I or II Essential Hypertension","enrollment":353},{"nctId":"NCT01983735","phase":"PHASE3","title":"Efficacy and Safety of TELMINUVO to Stage 2 Hypertension","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-01","conditions":"Hypertension","enrollment":200},{"nctId":"NCT01634295","phase":"PHASE3","title":"Efficacy and Safety of CKD-828 to Stage 2 Hypertension","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2012-07","conditions":"Hypertension","enrollment":103},{"nctId":"NCT01368536","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Hypertension, Stage 2 Hypertension, Diabetes","enrollment":975},{"nctId":"NCT01444885","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2011-10","conditions":"Variant Angina","enrollment":50},{"nctId":"NCT01237223","phase":"PHASE3","title":"Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Essential Hypertension","enrollment":1342}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1200402"},"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amlodipine (dummy)"],"phase":"marketed","status":"active","brandName":"Amlodipine placebos","genericName":"Amlodipine placebos","companyName":"Shenzhen Ausa Pharmed Co.,Ltd","companyId":"shenzhen-ausa-pharmed-co-ltd","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:59:36.935816+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}